65 results about "A549 cell" patented technology

The invention relates to lactobacillus reuteri HC1602 as well as a fungicide and application thereof, and belongs to the technical field of microorganisms. The lactobacillus reuteri HC1602 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.26890, the preservation date is March 23, 2023, and the address of the preservation institution is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The invention further provides application of the lactobacillus reuteri HC1602 in preparation of products for inhibiting and preventing respiratory syncytial viruses and application of the lactobacillus reuteri HC1602 in preparation of products for reducing cholesterol in blood. The lactobacillus reuteri HC1602 provided by the invention can be used for effectively inhibiting the invasion of RSV (Respiratory Syndrome Virus) to A549 lung cells and improving the survival rate of the A549 cells.

The invention discloses an SOD2 knockout cell line and application of the SOD2 knockout cell line in anti-poxvirus, and relates to the technical field of antiviral research. According to the invention, sgRNA of targeted superoxide dismutase 2 (SOD2) is designed, the sequence of the sgRNA is shown as SEQ ID NO.1-SEQ ID NO.2, then a stable SOD2 knockout human-derived non-small cell lung cancer A549 cell line is established by combining CRISPR / Cas9 gene editing with a lentiviral vector delivery technology, single-cell cloning is obtained through multiple rounds of puromycin screening, and the SOD2 gene knockout A549 cell strain is successfully constructed. Vaccinia virus Tian Tan strain infection shows that the number of plaques of SOD2 knockout cells is obviously greater than that of the plaques (about 2.3 times) of normal cell infection, and the plaques are relatively large, so that fine SOD2 has the effect of limiting intercellular transmission of poxvirus. The invention lays a foundation for research and preparation of antiviral drugs.

The invention discloses a polyketone compound derived from actinomycetes as well as a preparation method and application thereof, and relates to the technical field of microbial natural product mining and biological medicine, and the key point of the technical scheme is that the invention discloses a novel polyketone compound Strepactone derived from actinomycetes Streptomyces sp. DP0001, and the molecular formula of the novel polyketone compound Strepactone is C25H38O5. The compound is obtained through strain fermentation, ethyl acetate extraction and multi-step chromatographic purification, and the structure is identified through ESI-MS, 1H NMR and 13C NMR. Experiments show that Strepactone has an inhibition effect on staphylococcus aureus and methicillin-resistant staphylococcus aureus and has remarkable inhibition activity on human non-small cell lung cancer A549 cells, the half inhibitory concentration IC50 of the Strepactone is 5.36 mu M, and the Strepactone has no obvious cytotoxic activity on human embryo kidney cells 293T cells at the concentration of 30 mu M. The compound provided by the invention can be used for preparing anti-drug-resistant bacteria drugs and anti-human non-small cell lung cancer drugs, and also provides a structural basis for the development of novel antibacterial and anti-tumor leading drugs.

The application belongs to the technical field of medical preparations. The application provides a modified quantum dot Chlorella polyhedral composite material for radiotherapy sensitization, a preparation method and application. The preparation method comprises the following steps: preparing a doped tungsten-chromium gallate quantum dot with a chemical formula of Zn 0.98 Ga2O4:W 0.02 6+ ,Cr 0.02 3+ ; then, the doped tungsten-chromium gallate quantum dot is modified by amination, and then modified by a polysaccharide mixture composed of alpha-maltose, cellulose and sodium alginate; finally, the doped tungsten-chromium gallate quantum dot is co-incubated with Chlorella polyhedral to obtain the modified quantum dot Chlorella polyhedral composite material. The modified quantum dot can enter Chlorella polyhedral in a large amount, and the modified quantum dot in the material obtained by the application is not easy to overflow or fall off, and is easy to preserve, compared with the prior art. Meanwhile, the material obtained by the application has a very high killing effect on CT26 cells and A549 cells at a very low dose, and the cell apoptosis rates of the two kinds of cells are both more than 80%. Therefore, the application has a high industrial application prospect.

The present application provides the use of raltitrexed in the manufacture of a medicament for the treatment of diseases caused by adenovirus infection, including but not limited to respiratory tract infection, gastrointestinal infection and keratitis caused by adenovirus. When raltitrexed was tested for its anti-adenovirus activity at the cellular level, using a viral infection dose of 100 TCID50, the viral infectivity was determined on a human non-small cell lung cancer cell line (A549 cell) model, and the results showed that raltitrexed had a significant inhibitory effect on adenovirus, with an EC 50 = 8.98 nM, a CC 50 > 187.5 nM, and it was found that it had a significant inhibitory effect on the entry of the virus into the cell; and in the hDSG2 mouse model, a significant inhibitory effect of raltitrexed on viral replication was also observed. Therefore, raltitrexed can be used to treat diseases caused by adenovirus infection.

The present application relates to the technical field of medicine, in particular to the application of gansix triol A in the preparation of a drug for treating gastric cancer and / or non-small cell lung cancer, gansix triol A plays an anti-gastric cancer role by selectively inhibiting the proliferation of gastric cancer MGC-803 cells and inhibiting angiogenesis, the mechanism involves inhibiting the VEGF / VEGFR2 signal pathway and inducing cell apoptosis; the mechanism of gansix triol A in inhibiting the VEGF / VEGFR2 signal pathway is similar to that of bevacizumab; gansix triol A plays an anti-non-small cell lung cancer role by selectively inhibiting the proliferation of non-small cell lung cancer A549 cells, the mechanism involves inhibiting the MAPK / ERK signal pathway and inducing cell apoptosis. The present application finds that the cytotoxic activity of gansix triol A on MGC-803 cells and A549 cells is significantly stronger than that of tanshinone IIA; gansix triol A has an anti-tumor effect of "one drug with double targets, double inhibition" and "high efficiency and low toxicity".

The invention discloses a phenoxazine skeleton-containing drug small molecule and application thereof, and belongs to the technical field of synthesis of heterocyclic compounds and antitumor drugs, the phenoxazine skeleton-containing drug small molecule has an inhibition effect on HepG2 and A549, a phenoxazine derivative 7c with the third site connected with a methoxy group at the tail end of a phenoxazine structure benzene ring has a better overall effect, and the phenoxazine skeleton-containing drug small molecule can be applied to preparation of antitumor drugs. The inhibition rates of the compound on HepG2 and A549 are respectively 87.67% and 94.23%. 7g of the phenoxazine derivative of which the methyl ester structure is connected to the third site of the phenoxazine structure only has an obvious effect on A549, and the inhibition rate in A549 cells is 96.00%.

The invention provides a construction method of a non-small cell lung cancer histone H1.3 arginine methylation point mutation cell model. The construction method comprises the following steps: designing mutation primers H1.3 R80A-F and H1.3 R80A-R; the method comprises the following steps: by taking a pCDH-HA-H1.3-Flag plasmid as a template, carrying out PCR (Polymerase Chain Reaction) amplification by adopting a mutation primer, digesting a product by DMT enzyme, and converting a competent cell to obtain a mutant plasmid; and co-transfecting the mutant plasmid and a helper plasmid to a packaging cell, collecting a virus solution, filtering, infecting an A549 cell, adding Polybrene to assist infection, culturing, and screening a stably transfected cell strain by using puromycin to obtain the recombinant plasmid. The invention also provides application of the mutant cell model obtained by the construction method. According to the invention, the blank of histone H1.3 methylation research is filled, the 80th arginine is clear as a core modification site, and the established model provides a new tool for lung cancer mechanism research and drug research and development.

The invention discloses a nucleotide for inhibiting expression of ILKAP (Interleukin-7-Kinase Associated Protein) related circular RNA (Ribonucleic Acid) and application of the nucleotide, and the nucleotide is characterized in that the nucleotide sequence is CGUCAGUACUCGGGUUUCA, and the expression level of hsacirc0001116 can be specifically and obviously reduced. Experimental results prove that the nucleic acid molecule can effectively interfere with the expression of hsacirc0001116 in human non-small cell lung cancer A549 cells, and can significantly inhibit the survival of lung cancer cells. In addition, when the nucleic acid molecule is combined with an existing antitumor drug for use, a synergistic treatment effect can be generated.

The invention discloses a polyclonal antibody targeting a human CPNE7 variable splicing isomer and application of the polyclonal antibody, and belongs to the technical field of biological medicine. The antigen epitope 'KYKQKRRSYKN' (SEQ ID NO.1) capable of being targeted by the polyclonal antibody provided by the invention is positioned in a common conserved region of all main isomers of CPNE7, and a variable splicing region is not involved. The titer of the obtained antibody serum is as high as 1: 32,000, which indicates that the antibody has extremely high immunoreactivity and sensitivity and can be used for detecting trace proteins. The antibody disclosed by the invention can be used for effectively identifying GST-CPNE7 fusion protein expressed by a prokaryotic system and CPNE7-FL and CPNE7-S protein overexpressed in an eukaryotic system (A549 cells), and the applicability of the antibody in various experimental systems is proved. Therefore, the blank in the prior art can be filled, and a core tool is provided for research of the CPNE7 in the fields of tumor biology, diagnosis and treatment.

This invention provides the application of apatinib in the preparation of antiviral drugs, specifically involving the application of the anticancer drug apatinib in inhibiting the replication of Hantanensis virus (HTNV) and Chikungunya virus (CHIKV). Apatinib can significantly inhibit HTNV replication and reduce viral titers at the cellular level. Experiments have shown that after treatment with apatinib, the expression levels of viral structural proteins, the nucleic acid levels of HTNV, and the viral titers in the cell culture supernatant were significantly reduced in HTNV-infected A549 cells, while the drug exhibited low cytotoxicity. Furthermore, apatinib can also inhibit CHIKV replication. This invention provides a novel anti-HTNV candidate drug and offers insights for the rapid development of antiviral drugs.

The application relates to the technical field of aspirin pharmaceutical chemistry, in particular to an aspirin-sulfonamide hybrid, a preparation method and application thereof. The preparation method can synthesize a plurality of novel aspirin-sulfonamide hybrids by taking piperazine as a bridge, and by a three-step continuous method of "acyl chlorination, sulfonamidation and N-acylation" according to a "molecular hybridization principle". In the process, only one separation and purification is performed, and the preparation steps are simple. The aspirin-sulfonamide hybrid prepared by the method is most effective on human non-small cell lung cancer cells A549, and the activity is more than 33 times higher than that of a parent aspirin, and is similar to the activity of an anticancer drug irinotecan. The aspirin-sulfonamide hybrid 3k prepared by the method has a certain inhibitory effect on various cancer cells. The hybrid can induce human non-small cell lung cancer A549 cell apoptosis in a concentration-dependent manner, and can induce human non-small cell lung cancer A549 cell cycle arrest in the G0 / G1 phase, and inhibit cell growth.

The invention discloses a cyclic iridium-ester tin imidazo phenanthroline complex with an aggregation-induced emission (AIE) characteristic as well as a preparation method and an anti-cancer application of the cyclic iridium-ester tin imidazo phenanthroline complex. The structural formula is as shown in formula (I), R1 is phenyl or 3-pyridyl, and R2 is hydrogen or fluorine. By testing the growth inhibition rate of the target compound on human alveolar basal epithelial cancer cells (A549) and comparing, the target compound shows potential A549 cell proliferation inhibition activity. In addition, the target complex shows a unique AIE luminescence characteristic, and is accumulated in lysosome of A549 cells, resulting in lysosome damage and apoptosis.

The ranitidine hydrochloride causes the change of multiple vesicles of A549 cells. The invention relates to the technical field of drug ranitidine hydrochloride, and the drug ranitidine hydrochloride is found to have the effect of causing the change of multiple vesicles of cells for the first time, and mainly can cause the change of multiple vesicles of A549 cells. The technical problem to be solved is that ranitidine hydrochloride is utilized to treat A549 cells, and treatment conditions are changed to observe whether the drug can change the morphological structure of the A549 cells or not. The key point of the technical scheme for solving the problem is that after ranitidine hydrochloride with the concentration of 2.39 mmol / L, 4.78 mmol / L or 7.17 mmol / L is used for treating A549 cells for 24 hours, the morphological structure change of the cells is observed through a microscope. The main application is as follows: when ranitidine hydrochloride with the concentration of 4.78 or 7.17 mmol / L is used for treating A549 cells for 24 hours, remarkable multi-vesicle change can be triggered. After the drug with the concentration of 4.78 mmol / L causes the change of the multiple vesicles of the cells, the multiple vesicles disappear after being cultured in a culture solution without the drug for 24 hours. The medicine can be utilized to trigger the phenomena of the change of the multiple vesicles and the disappearance process of the multiple vesicles of the cells, the ultrastructure and the molecular mechanism formed by the vesicles are further researched, and the deep understanding of the formation and disappearance mechanism of the vesicles is facilitated.

The application discloses a butyl tin-cycloiridium phenanthroline complex with an aggregation-induced emission (AIE) property, a preparation method of the complex and anticancer application of the complex. The structural formula of the complex is shown as formula (I), and R is one of hydrogen, a phenyl group, a p-tolyl group, a p-bromophenyl group, a p-fluorophenyl group, a biphenyl group, a triphenylamine group, a carbazole group, a tetraphenyl ethene group and a triphenylbenzene group. The growth inhibition rates of the target compound on human alveolar basal epithelial carcinoma cells (A549) and cisplatin-resistant cells (A549 / DDP), cervical cancer cells (Hela) and human lung normal epithelial cells (BEAS-2B) are tested, and it is found through comparison that the target compound shows potential anticancer activity. In addition, the target compound shows unique AIE emission characteristics. The target compound mainly targets the lysosomes of A549 cells, and influences the mitochondria to cause the decline of the mitochondrial membrane potential, thereby showing anticancer activity.

This invention discloses a semi-sandwich structured ruthenium triphenylphosphine dithiocarboxylic acid complex with a simple preparation process and its applications. The complex has the structure shown in Figure (I), with the central ruthenium and... η 5 - Coordination with cyclopentadiene, triphenylphosphine, and dithiocarboxylic acid derivatives, wherein the dithiocarboxylic acid ligands are selected from ethyl xanthic acid, isopropyl xanthic acid, ... N,N Diethyldithiocarbamic acid, morpholine dithiocarbamic acid, and carbazole dithiocarbamic acid. This invention employs a simple one-step method of room temperature preparation and recrystallization purification using a ruthenium precursor and dithiocarbamic acid ligand. This method offers advantages such as readily available raw materials, mild reaction conditions, simple post-processing, and high yield. In vitro tests show that the complexes exhibit excellent anti-proliferative activity against non-small cell lung cancer A549 cells, significantly superior to cisplatin. The complexes demonstrate activity by reducing mitochondrial membrane potential, inducing intracellular reactive oxygen species accumulation, and arresting the cell cycle (G1 phase), leading to late apoptosis in A549 cells.

The invention relates to application of a pinellia ternate exosome in preparation of a medicine for resisting non-small cell lung cancer, and belongs to the technical field of Chinese herbal medicines. According to the application of the pinellia ternate exosome in preparing the non-small cell lung cancer resisting medicine, the non-small cell lung cancer resisting medicine is a tumor cell proliferation inhibitor, a tumor cell migration inhibitor or a tumor cell apoptosis accelerant. The Pinellia ternate exosome PEs is dispersed with normal saline, the effective concentration is 10-100 g / mL, the Pinellia ternate exosome PEs retains various active components of Pinellia ternate, the growth and proliferation ability and healing ability of non-small cell lung cancer cells A549 can be significantly inhibited, apoptosis of the cells A549 can be promoted, growth of tumor tissues of tumor-bearing mice can be inhibited, and the Pinellia ternate exosome PEs can be used for treating tumor-bearing mice. The important application prospect is realized in the treatment of the non-small cell lung cancer.

The invention discloses an application of a small molecule drug ATWLPPR Peptide TFA in resisting mycobacterium bovis infection, and belongs to the field of biological medicine, the small molecule drug ATWLPPR Peptide TFA is an agonist of a target host factor NRP1, and then the inhibition effect of the ATWLPPR Peptide TFA on mycobacterium bovis in vitro and in vivo is researched. An in-vitro bacterial loading titration result shows that the ATWLPPR Peptide TFA treatment can present dose-dependent inhibition of the mycobacterium bovis to adhere to A549 cells. Mouse experiment results show that ATWLPPR Peptide TFA treatment can inhibit mice from being infected with mycobacterium bovis, pathological injuries of mouse lung tissues are effectively relieved, and a brand new direction is provided for prevention and control of mycobacterium bovis.

The application discloses application of an ethanol extract of Camellia oleifera flower buds as an EGFR inhibitor in preparation of a drug for treating non-small cell lung cancer. In the application, the ethanol extract of Camellia oleifera flower buds for treating non-small cell lung cancer is obtained by extracting Camellia oleifera flower buds with a solvent of 70% ethanol. The ethanol extract can inhibit EGFR kinase activity, can be used as an EGFR inhibitor, can inhibit proliferation of non-small cell lung cancer A549 cells by inducing G1 phase arrest, can induce apoptosis and inhibit migration and invasion through a mitochondria-mediated pathway, and can further play an antitumor role, and has a prospect of new drug research and development for treating non-small cell lung cancer.

The invention provides a ganoderma lucidum molecular ecological liquid extract obtained through specific fermentation and a preparation method and application thereof, and belongs to the technical field of microbial fermentation. According to the method, an improved fermentation culture medium is adopted, 5-8% of CO2 is introduced, fermentation is performed for 90-180 days at the temperature of 30-32 DEG C under the condition that the concentration of dissolved oxygen in the environment is kept to be 20-30%, and after purification, the extract of the ganoderma lucidum molecular ecological liquid is obtained. According to the myxomycete molecular ecological liquid prepared by the preparation method provided by the invention, the content of active ingredients for relieving the symptoms of the chronic obstructive pulmonary disease can be remarkably increased; moreover, an in-vitro cell experiment verifies that the extract of the ganoderma lucidum molecular ecological liquid has an inhibition effect on an A549 cell line, and an animal experiment further proves that the extract of the ecological liquid can regulate and control the expression level of proinflammatory cytokines, so that lung inflammation is inhibited, pathological injury of lung tissues is relieved, and local abnormal conditions of the lung are improved.

The invention provides a TB derivative with photodynamic antibacterial and anti-tumor activity and a synthesis method thereof, the derivative comprises a carbazole-TB-thiophene-pyridinium derivative, the structural formula of the derivative is shown in the specification, and the four derivatives have good viscosity response and aggregation-induced emission property and can efficiently and synchronously generate I-type and II-type active oxygen. The TB-CB-1, the TB-TPA-1 and the TB-TPA-2 have good photodynamic antibacterial activity on tested gram positive bacteria (G + bacteria), and the antibacterial rates of the TB-CB-1, the TB-TPA-1 and the TB-TPA-2 on the three kinds of G + bacteria are all larger than 90% when the concentration of the TB-CB-1, the TB-TPA-1 and the TB-TPA-2 is 2 mol. L <-1 >. The four compounds have strong photodynamic anti-tumor activity and large light and dark toxicity difference, the IC50 values of the TB-CB-1 to MCF-7, A549 and HepG2 cells are all greater than 100 [mu] g.mL <-1 > in the absence of illumination, and the IC50 values are respectively reduced to 1.53 [mu] g.mL <-1 > and 0.28 [mu] g.mL <-1 > under illumination; the IC50 of the TB-TPA-2 to A549 cells under a dark condition is greater than 200 [mu] g.mL <-1 >, and the illumination is reduced to 2.01 [mu] g.mL <-1 >. The invention provides a new thought for design and synthesis of a novel photodynamic antibacterial / antitumor photosensitizer.

The invention discloses synthesis and antitumor activity research of a novel drug small molecular formula (1) containing an indole structure, wherein R is as follows: 5-acetylvaleric acid is used as a starting raw material, then Fischer reaction, methylation reaction and hydrolysis reaction are performed to obtain 4-(5-(tert-butyl)-1, 2-dimethyl-1H-indole-3-yl) butyric acid, and the 4-(5-(tert-butyl)-1, 2-dimethyl-1H-indole-3-yl) butyric acid is used as a raw material. The compound is coupled with different amine compounds to obtain a target compound. A target compound is subjected to a CCK-8 experiment, and a conclusion is obtained that the target compound 6f and 5-fluorouracil are tested at the concentration of 20 [mu] M within 6a-6 h, and it can be known that the compound 6f has the best inhibition effect on A549 cells, Hela cells and A549 cells. IC50 value calculation is carried out on a target compound under various concentrations, the IC50 value of 6c to Hep G2 cells is minimum and the inhibition effect is best, and the IC50 value of 6f to A549 cells and Hela cells is minimum and the inhibition effect is best.

The present application relates to a lactobacillus reuteri HC1602, a bacterial agent and application thereof, and belongs to the technical field of microorganisms. Limosilactobacillus reuteri The lactobacillus reuteri (HC1602) is preserved in the China General Microbiological Culture Collection Center, with a preservation number of CGMCC No. 26890, a preservation date of March 23, 2023, and an address of the preservation agency of No. 3, Beichen West Road, Chaoyang District, Beijing. The present application also provides an application of the lactobacillus reuteri HC1602 in preparing a product for inhibiting and preventing respiratory syncytial virus and an application in preparing a product for reducing cholesterol in blood. The lactobacillus reuteri HC1602 provided by the present application can effectively inhibit the invasion of RSV on A549 lung cells and improve the survival rate of A549 cells.

The invention discloses a choline acetylase (ChAT) sensor constructed on the basis of manganese dioxide nanosheets (MnO2NSs) and application of the choline acetylase (ChAT) sensor in lung cancer A549 cells. According to the method, MnO2NSs and oxidation-state TMB (oxTMB) are reduced at the same time through CoA, MnO2NSs are reduced into Mn < 2 + >, catalytic activity is lost, and TMB cannot be catalyzed to be oxidized into blue oxTMB. Along with the increase of the CoA concentration, the color of the solution becomes light, and the ultraviolet absorption peak at 652nm is reduced, so that the ultraviolet colorimetric detection of CoA is realized. In addition, the change of the color of the solution causes the change of R, G and B values, and the CoA detection by the smart phone is realized through the relationship between the B / G value and the CoA concentration. ChAT can catalyze choline and acetyl coenzyme A (Ac-CoA) to generate CoA, and detection of ChAT is indirectly realized according to signal change caused by the generated CoA. The alpha-NETA can inhibit the activity of ChAT and reduce the generation of CoA, so that the inhibition effect of the alpha-NETA is evaluated. The method is applied to analysis of ChAT content in lung cancer cells, and has the advantages of visualization, simplicity in operation, high sensitivity and good specificity.

The invention relates to a composition for detecting lung adenocarcinoma cells through cascade cell-assisted enhanced fluorescence signals, a kit and application, and belongs to the technical field of biological medicine. The composition for detecting the lung adenocarcinoma cells by using the cascaded cell-assisted enhanced fluorescence signal comprises a biotin-modified EpCAM antibody, a streptavidin magnetic bead, a dual-aptamer probe R1-S1, a dual-aptamer probe S1-S2, a CCRF-CEM cell, a substrate and a dual-cholesterol probe marked with streptavidin beta-galactosidase, wherein the biotin-modified EpCAM antibody, the streptavidin magnetic bead, the dual-aptamer probe R1-S1, the dual-aptamer probe S1-S2, the CCRF-CEM cell, the substrate and the dual-cholesterol probe are connected with the substrate; wherein in the dual-aptamer probe R1-S1, R1 is used for targeting lung adenocarcinoma cells, and S1 is used for targeting CCRF-CEM cells; and S2 in the dual-aptamer probe S1-S2 is used for targeting CCRF-CEM cells. According to the invention, A549 cells are captured based on an EpCAM antibody indirect capture method, and multiple amplification of detection signals is realized by further utilizing a cascaded cell-assisted fluorescence signal enhancement strategy.

The invention discloses a multifunctional nanoprobe for lung cancer drug resistance diagnosis and treatment and a preparation method and application thereof, and relates to the technical field of DNA nanoprobes, the multifunctional nanoprobe comprises a Y-shaped structure formed by self-assembly of three nucleic acid chains S1, S2 and S3 and PTX, the Y-shaped structure and PTX are self-assembled to form a spherical structure, and the particle size of the spherical structure is 80-120nm; the S1 nucleic acid chain is loaded with an anti-ABCB1 sequence, is modified with a Cy5 fluorophore and is subjected to fluoro modification treatment; the S2 nucleic acid chain is loaded with an S6 sequence of a targeted A549 cell membrane surface specific structure; and the S3 nucleic acid chain is loaded with an anti-beta III-tubulin sequence. By integrating multiple functions of targeting recognition, gene silencing and chemotherapy drug delivery, diagnosis and treatment integration of the paclitaxel drug-resistant lung cancer is realized.

The invention discloses an aggregation-induced emission (AIE) type cyclic iridium-butyltin phenanthroline complex with adjustable luminescence color as well as a preparation method and anti-cancer application of the AIE type cyclic iridium-butyltin phenanthroline complex. The structural formula of the complex is shown as a formula (I), and C and N ligands are 2-(2, 4-difluorophenyl) pyridine, 2-phenylpyridine, 2-phenylquinoline, 2-(naphthalene-2-yl) quinoline and 3-(6-phenanthroline)-N, N-diphenyl aniline. By testing the growth inhibition rate of the target complex to human alveolar basal epithelial cancer cells (A549 cells) and comparing, the target complex shows potential anti-cancer activity. Besides, the target complex shows unique AIE characteristics, adjustable fluorescence emission with the wavelength of 540-680 nm is achieved, mitochondria of A549 lung cancer cells can be targeted, mitochondrial membrane potential is reduced, cell apoptosis is induced, and anticancer activity is shown.

The application discloses a phenoxazine skeleton-containing drug small molecule and application thereof, and belongs to the technical field of synthesis of heterocyclic compounds and antitumor drugs. The phenoxazine skeleton-containing drug small molecule has inhibitory effects on HepG2 and A549. The phenoxazine derivative 7c containing a methoxy group connected to the third position at the end of a benzene ring of a phenoxazine structure has a better overall effect, and the inhibitory rates on HepG2 and A549 are 87.67% and 94.23% respectively. The phenoxazine derivative 7g with a methyl ester group connected to the third position of a phenoxazine structure has an obvious effect on A549 only, and the inhibitory rate in A549 cells is 96.00%.

The application discloses a PKR gene knockout cell line and a construction method and application thereof. The construction method comprises the following steps: A1, designing sgRNA primers for PKR gene knockout; A2, performing single enzyme cutting treatment on LentiCRISPR v2 plasmid to obtain enzyme cutting products; A3, performing annealing hybridization reaction by using the synthesized sgRNA primers to obtain annealing hybridization products; A4, performing a ligation reaction on the enzyme cutting products and the annealing hybridization products, and transforming the obtained reaction products into competent cells to obtain a recombinant transfer plasmid; and A5, after performing lentivirus packaging on the recombinant plasmid, infecting A549 cells by using the obtained lentivirus liquid to obtain the PKR gene knockout cell line. The application successfully constructs the A549 cell line with the PKR stable knockout, the A549 cell line can inhibit the type I interferon induced by NDV, promote virus replication and induce more serious cell death, and thus can be applied to the development of NDV vaccines.

The invention discloses a radix ophiopogonis decoction anti-pulmonary fibrosis active component separated based on a centrifugation-membrane dialysis method and application of the radix ophiopogonis decoction anti-pulmonary fibrosis active component. Belongs to the field of ophiopogon root soup. The invention aims to solve the problem that the research on the ophiopogon root decoction mostly focuses on component analysis, pharmacological effect and the like in the prior art. The precipitation phase state, CP-I, CP-II and true solution phase state of the ophiopogon root decoction are successfully separated by adopting a centrifugation-membrane dialysis method. The results of qualitative and quantitative analysis of chemical components show that CP-I is closer to D, D, CP-I can more effectively improve PF symptoms compared with CP-II, and D, CP-I and CP-II do not cause damage to A549 cells and inhibit proliferation of the A549 cells induced by TGF-beta1 to different degrees. Compared with CP-II, the D and CP-I can more remarkably inhibit phosphorylation of protein Smad2 / 3, and the D, CP-I and CP-II can weaken the EMT of A549 cells induced by TGF-beta1 by blocking a TGF-beta1 / Smad pathway. CP-I is an effective phase state of the ophiopogon root decoction.